The FDA has cleared NanoString Technologies to market its Prosigna Breast Cancer Prognostic Gene Signature Assay, which runs on the company's nCounter Dx Analysis System. The assay is used to assess distant recurrence-free survival in postmenopausal women with certain types of breast cancer 10 years after undergoing surgery, the company said.

Related Summaries